Reports From the Field: White Paper addresses HIPAA concerns, disease management
A comprehensive analysis of the Health Insurance Portability and Accountability (HIPAA) and its impact on disease management has concluded that the new privacy regulations will not hamper disease management programs, according to the Disease Management Association of America (DMAA).
The association’s White Paper concluded that the U.S. Department of Health and Human Services has fully safeguarded the ability of legitimate disease management programs to use and disclose protected health information for activities within the DMAA’s industry consensus of disease management.
"While a lot of things in HIPAA are still unclear, disease management is not one of them. The White Paper’s legacy will be to eliminate any concern that disease management cannot coexist with strong patient privacy protections, that disease manager somehow hinder or is hindered by privacy. Neither is true, and this initiative finally proves it," says Warren Todd, DMAA’s executive director. The document may be obtained free of charge from DMAA. See their web site at www.dmaa.org.
A comprehensive analysis of the Health Insurance Portability and Accountability (HIPAA) and its impact on disease management has concluded that the new privacy regulations will not hamper disease management programs, according to the Disease Management Association of America (DMAA).You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content